162394-19-6

Basic information

• Product Name: Palifermin
• Synonyms: palifermin;24-163-Keratinocyte growth factor (human);Kepivance;24-163 Fibroblast growth factor 7 (human);Unii-qms40680K6
• CAS NO: 162394-19-6
• Molecular Weight: 0
• Mol File: 162394-19-6.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Palifermin(CAS DataBase Reference)
• NIST Chemistry Reference: Palifermin(162394-19-6)
• EPA Substance Registry System: Palifermin(162394-19-6)

Safety Data

• Hazardous Substances Data: 162394-19-6(Hazardous Substances Data)

Usage

Description

Palifermin, also known as Kepivance, is a recombinant human keratinocyte growth factor (KGF) used to treat mucositis, an inflammation of the oral and gastrointestinal mucosa often induced in patients receiving high-dose chemotherapy and radiotherapy for hematological malignancies. As a member of the heparin-family of fibroblast growth factors, palifermin provides protection from the damaging effects of chemotherapy and radiation by selectively promoting epithelial cell proliferation, leading to an increased rate of healing. It is produced by recombinant DNA technology utilizing an expression vector encoding KGFdes-23, an N-terminal truncated version of endogenous KGF with amino acids 1-23 deleted, which results in greater stability while retaining biological activity.

Uses

Used in Oncology:
Palifermin is used as a therapeutic agent for the treatment of mucositis in patients receiving high-dose chemotherapy and radiotherapy for hematological malignancies. It helps alleviate the debilitating side effects of these treatments, such as swallowing difficulty, potential infections, overuse of opioid analgesics, and extended hospitalization, by promoting epithelial cell proliferation and increasing the rate of healing.
Used in Stem Cell Transplant Patients:
Palifermin is also used as a supportive care agent for patients undergoing stem cell transplants, who are at a higher risk of developing mucositis. By mitigating the damaging effects of chemotherapy and radiation on the oral and gastrointestinal mucosa, palifermin can improve the patient's quality of life and potentially reduce the duration of hospitalization.
Used in Head and Neck Cancer Patients:
Palifermin is used as a treatment option for patients with head and neck cancer who are undergoing high-dose chemotherapy and radiotherapy. It can help manage the side effects of these treatments, such as pain and inflammation, by promoting the healing of the oral and gastrointestinal mucosa.
Dosage and Administration:
The recommended dosage of palifermin is 60 μg/kg/day, delivered by intravenous (i.v.) bolus injection, for 3 consecutive days before and three consecutive days following myelotoxic therapy, ensuring that the third dose is delivered greater than 24 hours before the commencement of the myelotoxic therapy. No formal drug-drug interaction studies have been conducted with palifermin.

Originator

Amgen (US)